Document:

Letter Agreement

 Exhibit 10.28 
  

					
		  	SCO FINANCIAL GROUP LLC	  	

 March 1, 2005 
 Bridge Oncology Products, Inc. 
 1285 Avenue of the Americas 
 35th Floor 
 New York, NY 10019 
  

			
	Attention:	  	Steven H. Rouhandeh
	Title:	  	Chairman

 Dear Sirs: 
 The purpose of this letter is to confirm the appointment of SCO Financial Group LLC (“SCO” or the “Advisor”) upon the terms and conditions set forth herein as exclusive financial consultant and advisor to Bridge Oncology
Products, Inc. (“the Company”) in connection with the Company’s general corporate financial management and advisory needs. In this connection, SCO, in its capacity as advisor, will assist the Company by undertaking certain activities,
to the extent that such activities are required by the status of a project, including the following: 
  

	 	1)	Meet with appropriate Company management to discuss and help the Company formulate an appropriate strategy, familiarization of product and technology, milestones, etc.;

  

	 	2)	Perform management services on an as needed basis, including accounting, financing, interface with legal counsel, etc.; 

  

	 	3)	Advise the Company with respect to business development and technology licensing, including the identification and due diligence of potential in-licensing opportunities, and
development of appropriate structure of a proposed transaction and assistance in the negotiations; 

  

	 	4)	Advise the Company with respect to mergers and acquisitions, including identification of counterparties, approach strategy and structure, and assist in the negotiations;

  

	 	5)	Advise the Company with respect to financing strategy, including public and private equity and debt; 

  

	 	6)	Advise the Company with respect to financial and trade media relations, including development of presentation materials, introduction to and scheduling of meetings with investment
managers and brokers, and analysis of ownership; 

 1285 AVENUE OF THE
AMERICAS, 35TH FLOOR, NEW YORK, NEW YORK 10019 
 Telephone: 212-554-4158 Fax: 212-554-4058 

 Bridge Oncology Products, Inc. 
 March 1, 2005 
 Page 2 
  

	 	7)	Assist in such other capacity as may be reasonably requested by the Company to effect the foregoing. 

 It is the practice of SCO to provide financial advice with respect to corporate finance partially on a retainer basis. Our retainer for services to be
rendered hereunder is $12,500.00 per month (which shall accrue until a financing of at least $5 million), payable at the beginning of each month. Additionally, SCO will be granted 250,000 seven-year warrants to purchase the Company’s common
stock (at $0.001 per share, based upon an assumed valuation of $2.5 million — 2.5 million shares at $1.00 per share ) upon execution of this agreement, and an additional 150,000 seven-year warrants (at the same exercise price) every 12-month
anniversary of the execution of this agreement. The warrants will be in a form acceptable to SCO, with cashless exercise provisions, etc. 
 In the event a corporate finance transaction contemplated in items 3) or 4) above is completed with any party which SCO identified, approached or negotiated with on behalf of the Company during the term of this engagement, the Company will
pay SCO a success fee for its advisory services of 5% of the Aggregate Value of the transaction. Additionally, the Company agrees to reimburse SCO for its out-of-pocket expenses incurred in connection with the Advisor’s role in the transaction
in the amount of 1% of the Aggregate Value of the transaction. SCO will have the option of receiving its success fee in cash or in seven-year warrants to purchase the Company’s common stock (at $0.001 per share, based upon an assumed valuation
of $2.5 million). 
 In the event a corporate finance transaction contemplated in item 5) above is completed with any party which SCO
identified, approached or negotiated with on behalf of the Company, the Company will pay SCO a success fee of 7% in cash (plus warrant coverage, at sale price of the common stock, of 10%) of the Aggregate Value of the transaction. The agent warrants
will be in a form acceptable to SCO, with cashless exercise provision. Additionally, the Company agrees to reimburse SCO for its expenses in connection with SCO’s role in the transaction in the amount of 1% of the Aggregate Value of the
transaction. 
 For the purposes of this letter, the term Aggregate Value shall mean the total amount of cash and the fair market value of
all other property paid or payable, directly or indirectly, to the Company and its security holders. In addition, Aggregate Value shall include the net amount of any debt and/or contingent liability repaid or assumed by the purchaser from the
Company, both directly or indirectly. 
 For purposes of this letter, a “transaction” shall mean any transaction or series or
combination of transactions, other than in the ordinary course of trade or business, whereby, directly or indirectly, a significant portion of the capital stock of the Company or a significant portion of its respective assets is transferred for
consideration, including without limitation, a sale or exchange of capital stock or assets, a lease of assets with or without a purchase option, a merger or consolidation, a tender or exchange offer, a leveraged buy-out, the formation of a joint
venture, minority investment or partnership, a licensing deal or any similar transaction. 

 Bridge Oncology Products, Inc. 
 March 1, 2005 
 Page 3 
 In
addition to any fees payable to SCO under the terms of this letter, the Company agrees to reimburse the Advisor, upon a monthly basis, for its out-of-pocket expenses incurred in connection with the Advisor’s activities under this letter.

 The Company agrees to indemnify SCO and each of its respective affiliates and their respective directors, officers, employees, agents and
controlling persons (each such person being an “Indemnified Party”) from and against any and all losses, claims, damages and liabilities, joint or several, to which such Indemnified Party may become subject under any applicable federal or
state law, or otherwise, related to or arising out of any transaction contemplated by this letter or the engagement of the Advisor pursuant to, and the performance by the Advisor of the services contemplated by, this letter and will reimburse any
Indemnified Party for all expenses (including counsel fees and expenses, whether incurred in connection with third party claims or direct claims against the Company) as they are incurred in connection with the investigation of, preparation for or
defense of any pending or threatened claim or any action or proceeding arising therefrom, whether or not such Indemnified Party is a party. The Company will not be liable under the foregoing indemnification provision to the extent that any loss,
claim, damage, liability or expense is found in a final judgment by a court of competent jurisdiction to have resulted primarily from the Advisor’s bad faith or gross negligence. 
 If a transaction is consummated by the Company with any party which the Advisor identified, approached or negotiated with on behalf of the Company within
two years from the date of termination of this agreement, or any amendment or extension thereto, the Company agrees to pay the Advisor a transaction fee determined as provided in the foregoing paragraphs. In the event that the Company is acquired
during the term of the engagement, the agreement will survive the merger and the successor company will subject to the terms and provisions of this agreement relating to the payment of fees, expenses and indemnification. 
 The Advisor’s engagement hereunder may be terminated by either the Company or the Advisor upon the first day of any month upon thirty days written
notice to that effect to the other party, it being understood that the provisions relating to the payment of fees, expenses and indemnification will survive any such termination. Provided, however, in the event a transaction contemplated in items
3), 4) or 5) is completed the minimum term of the engagement will extend 24 months from the closing date of the transaction. 
 This
agreement shall be construed and interpreted in accordance with the laws of the State of New York. 

 Bridge Oncology Products, Inc. 
 March 1, 2005 
 Page 4 
 If the foregoing is in accordance with your understanding, please confirm acceptance by signing and returning to us the
duplicate of this letter attached herewith. 
  

			
	SCO FINANCIAL GROUP LLC
		
	 By:
	 	 /s/ Jeffrey B. Davis

	 Name:
	 	 Jeffrey B. Davis

	 Title:
	 	 President

	
	BRIDGE ONCOLOGY PRODUCTS, INC.
		
	 By:
	 	 /s/ Steven H. Rouhandeh

	 Name:
	 	 Steven H. Rouhandeh

	 Title:
	 	 ChairmanConsulting Agreement

 Exhibit 10.29 
 SOMANTA LIMITED 
 July 19, 2005 
 Dr. Balbir Brar 
 26261 Glen Canyon Drive 
 Laguna Hills, CA 92653 
 Dear Bal: 
 The purpose of this letter is to memorialize the agreement reached between Somanta Limited (the “Company”) and you related to your engagement as an independent
consultant to the Company. The parties acknowledge and agree that the Company intends to enter into a Share Exchange Agreement with Bridge Oncology Products, Inc. (“Bridge”) whereby the Company will become a wholly-owned subsidiary of
Bridge. At such time, this letter agreement shall be assumed by Bridge and Bridge shall fulfill the Company’s obligations hereunder and references herein to the “Company” shall thereafter be references to Bridge. If you agree to be
bound by the terms and conditions set forth in this letter, please countersign this letter below. 
 As indicated above, you will be an independent
consultant to the Company. You acknowledge and agree that your Services Agreement dated October 11, 2004 by and between you and Somanta Limited shall terminate and be of no further force or effect as of the date of this letter agreement. Your
responsibilities as an independent consultant of the Company will include, but not be limited to, assisting and facilitating the manufacture of Alchemix in India and to assist in transitioning such responsibilities to the Company’s Vice
President of Pre-Clinical Affairs. You will report to the Company’s Chief Executive Officer and will have the title of Senior Scientific Advisor. The Company will not exercise any control over the manner or methods with which you perform such
services. The Company’s sole interest and responsibility is to ensure that the services covered by this letter agreement are performed and rendered in a competent, satisfactory and legal manner. 
 Your effective start date will be June 1, 2005. You will devote such time as may be necessary, in your discretion, to fulfill your responsibilities as an
independent consultant to the Company which shall in no event be less than five (5) business days per month. 
 In consideration for your consulting
services, the Company will reimburse you for all reasonable expenses incurred in performing services to the Company pursuant to this letter agreement. In order to be reimbursed for such expenses, however, you must provide the Company with the
relevant receipts detailing such expenses. You will not receive any other cash compensation during the term of your consultancy, nor will you be eligible for any vacation pay, sick leave, retirement benefits, social security, workers’
compensation disability benefits, unemployment benefits or any other employee benefit of any kind. However, you will be paid a bonus as follows: (i) if the Company closes an equity or debt financing with aggregate gross proceeds to the Company
of at least $10,000,000 during the period of your consultancy with the Company (the “Qualified Financing”), you will be paid a bonus at such closing equal to $5000 multiplied 

 
by the number of months that have elapsed between the date of this letter agreement and the date of the closing of such Qualified Financing, prorated for any
partial month, plus $8000 or (ii) if the Company terminates this letter agreement and your consultancy other than for “Cause,” you will be paid a bonus equal to $5000 multiplied by the number of months that have elapsed between the
date of this letter agreement and the effective date of such termination, prorated for any partial month, plus $8000; provided, however, that in no event will any such bonus exceed an amount equal to six (6) months multiplied by $5,000, plus
$8,000. For purposes of this letter agreement, the term “Cause” shall mean, as determined by the Company’s Board in good faith: (i) consultant’s material breach of this letter agreement, (ii) consultant’s willful
misconduct or gross negligence in the performance of consultant’s duties, (iii) consultant’s conviction of or entering of a plea of guilty or no contest to a felony, or (iv) the order of a regulatory agency that the consultant be
removed from any authority with the Company. Subsequent to a Qualified Financing, you will be paid $5000 per month in arrears until such time as this agreement is terminated or expires. 
 In addition, upon the closing of the pending share exchange between the Company and Bridge, your option to purchase shares of Somanta Limited will be cancelled, and the Bridge will replace it with an option to
purchase the Bridge’s common stock as set forth in the Share Exchange Agreement between the Company, Bridge, the shareholders of Somanta Limited and the optionholders of Somanta Limited. In general, the number of shares of Bridge common stock
that your new Bridge option will cover will equal the number of shares of Somanta Limited common shares your existing option covers (i.e., 6,000,000) multiplied by the exchange ratio applicable to all Somanta Limited shareholders and optionholders.
The exercise price will be determined by dividing $0.09 (which is 5p multiplied by the exchange rate in effect today) by the exchange ratio applicable to all shareholders and optionholders of Somanta Limited; provided, however, that such Bridge
option shall be fully vested. 
 During the period of your consultancy the Company acknowledges and agrees that you may engage in other employment,
occupation, consulting or other business activity so long as it is not directly related to or in competition with the business of the Company or any business the Company may become involved in during your period of your consultancy, nor will you
engage in any activities that are in conflict with the operations or obligations of the Company. 
 This letter agreement may be terminated, with or without
Cause, by either party upon sixty (60) days advance written notice. 
 This letter agreement shall be construed by and interpreted under the laws of the
State of Delaware without respect or reference to its principles of conflicts of laws. This letter agreement may be modified, amended or supplemented only by a written instrument duly executed by all parties hereto. This letter agreement constitutes
the entire understanding between the parties and supersedes all prior or contemporaneous discussions between the parties regarding the subject matter hereof. If any provision of this letter agreement, portion of such provision, or the application
thereof to any person or circumstance, shall, to any extent, be held invalid, illegal or unenforceable, the remainder of this letter agreement or the remainder of such provision and the application thereof to other persons or circumstances, other
than those as to which it is held invalid, illegal or unenforceable, shall not be affected thereby, and each term and provision of this letter agreement shall be valid and be enforced to the fullest extent permitted by law. This 

  

 2 

 
letter agreement may be executed in multiple counterparts, each of which when it is executed and delivered shall be deemed an original, and such counterparts
together shall constitute one instrument. The parties hereto agree to accept facsimile signatures to evidence the execution of this letter agreement. 
  

			
	 Regards,

		
	 By:
	 	 /s/ Terrance J. Bruggeman

		 	 Terrance J. Bruggeman, Chairman

	
	Acknowledged and Agreed:
		
	  	 	 /s/ Balbir Brar

		 	 Balbir Brar

  

 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00105-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00105-of-00352.parquet"}]]